We found that the antibody levels of six seromarkers (BLRF2-IgA, BLRF2-IgG, BDLF1-IgA, BDLF1-IgG, EBNA1-IgA, BLLF3-IgA) in patients with NPC were significantly higher than those in the benign controls and healthy controls, and most of these antibodies were also elevated in the serum of patients with early-stage NPC (Fig. 4, Supplemental Figs. S1 and S2). This evidence concerns the gene CD79A and nasopharyngeal carcinoma.